SUMMARY. Elevated concentrations of asialylated LDL (asialo-LDL) have been reported in patients with coronary artery disease (CAD). This may stimulate lipid accumulation in arterial intima cells and promote atherosclerosis. To investigate asialo-LDL as a potential risk-factor for coronary atherogenesis, we developed an antibody-lectin sandwich assay to measure levels in serum from CAD patients and age-matched control subjects. LDL was captured with an anti-apolipoprotein (apo) B antibody and asialylated oligosaccharides measured using the biotinylated 0-galactose (n-gal) binding lectin, Ricinus communis agglutinin 120 (RCA I2o ) , and a streptavidin-alkaline phosphatase conjugate. For the control and atherosclerotic subjects, median [interquartile range (IQR)] values for total concentrations of asialo-LDL were 240mg/L (l8Q.-3IOmg/L) and 220mg/L (l86-390mg/L), respectively (P=Q·82). When expressed as a percentage of serum apo B-100, median (lQR) values were 18% (16-23%) and 19% (15-29%), respectively (P=0·78). These results suggest asialo-LDL has little value as a risk factor for coronary atherosclerosis.
INTRODUCTION
High levels of circulating LDL are an independent risk factor for the development of atherosclerotic disease. However. it has now been established that post-secretory modifications are required to create LDL particles with an atherogenic phenotype. 1.2 In addition to oxidative modifications. a number of studies have revealed the presence of significantly increased concentrations of asiaIylated LDL (asialo-LDL) in the blood of patients with coronary atherosclerosis compared with control subjects.' 7 Low-density lipoprotein prepared from such patients has been found to contain between I· 5-and 5'0-fold lower levels of sialic acid compared with LDL from healthy volunteers. Elevated concentrations of asialo-LDL have also been reported in patients with type 1 and type 2 diabetes," who frequently develop both coronary and extra-coronary complications.
Investigations in vitro have found that sialic acid-poor LDL from coronary artery disease (CAD) patients, and LDL desialylated by treatment with neuraminidase, induces the rapid accumulation of lipid in cell types found within the arterial intima. such as endothelial cells, monocytes, macrophages and smooth muscle cells."!" In addition, the sialic acid content of LDL has been inversely correlated with the avidity of LDL for negatively charged arterial proteoglycans. I I This is especially interesting since interactions between LDL and proteoglycans can lead to the formation of insoluble complexes that stimulate the rapid accumulation of lipid in macrophages.'? On the basis of such observations, reductions in sialic acid content have been proposed as an additional modification of LDL important in foam cell formation and atherosclerotic plaque development.f-' Consequently, elevated serum concentrations of asialo-LDL may be an important risk factor for atherosclerosis.
Low-density lipoprotein sialic acid is found predominantly as the terminal sugar on the Nlinked complex biantennary oligosaccharides of apolipoprotein (apo) 8-100,13 although a smaller proportion is associated with lipid glycoconjugates." Removal of terminal sialic acid residues results in the exposure of n-galactose (n-gal) sugars within the N-acetyllactosamine sequences of apo B-100. As a result, n-gal binding lectins can be used to study sialic acid depletion of LDL. Previous investigations have found the lectin Ricinus communisagglutinin 120 (RCA I2o) to be extremely useful for the analysis of asialo-LDL, due to its high affinity for terminal n-gal residues on apo B-100 and negligible interaction with other oligosaccharide components, such as n-mannose, N-acetyl-o-glucosamine and sialic acid.4.14.IS To date, most studies use RCA I20 immobilized to a Sepharose" (Amersham Pharmacia Biotech UK Ltd, Little Chalfont, UK) or agarose matrix so asialo-LDL can be analysed by affinity chromatography,4.9.10.14.15 although this can prove quite time-consuming when processing large numbers of samples. A microtitre plate method has also been described for the measurement of asialo-LDL in purified LDL fractions and serum. 16 This assay employs immobilized RCA I20 and an antibody-conjugate to detect captured apo B-IOO.
We have developed an alternative microtitre plate assay for the analysis of asialo-LDL. In this technique, LDL is captured from the sample by an immobilized apo B antibody and asialylated oligosaccharides on the lipoprotein measured using biotinylated RCA I2o. This sandwich assay was applied to serum from patients with coronary artery stenosis and agematched controls, and the potential of asialo-LDL as a risk factor for CAD assessed.
MATERIALS AND METHODS
Subjects for study This study was conducted in compliance with the Declaration of Helsinki (1996) and was approved by the Ethics Committee of the Queen's University of Belfast. All patients gave consent for their blood to be taken for the study. Blood samples were obtained from 30 patients (20 men and 10 women) aged 44-79 years with angiographically-confirmed CAD and from 30 control subjects (12 men and 18 women) aged 13-74 years with no clinical history of CAD or chest pain. The characteristics and serum lipid profile of both populations used in this study are shown in Table I and apo B-100. Although the control group had a lower ratio of men to women compared with the CAD population, this was not statistically significant.
Chemical reagents
All chemicals (Analar grade) were obtained from Merck (Poole, UK) unless stated otherwise.
Blood sample collection For the preparation of plasma and serum, venous blood was drawn (after an overnight fast) into tubes containing disodium EDTA or tubes with no anti-coagulant, respectively. Plasma was quickly processed for the preparation of LDL while the serum was aliquoted and immediately frozen at -70°C in the presence of 10% sucrose." Serum samples were stored no longer than 6 months before analysis.
Blood lipoprotein profile Concentrations of total serum cholesterol and triglycerides were measured by standard enzymatic techniques on a Vitros 750 spectrum analyser (Johnson and Johnson Clinical Diagnostics, Rochester NY, USA). Serum HDL cholesterol was measured following magnesiumdextran precipitation," while LDL cholesterol was calculated using the Friedewald formula.'? Apolipoprotein B-100 concentrations were determined by immunoturbidimetric assay (Randox Laboratories, Crumlin, UK) on a Cobas FARA analyser (Roche, Basel, Switzerland).
Preparation and desialylation of LDL Low-density lipoprotein (d = 1,019-1,063 kg/L) was isolated from the plasma of a young healthy normolipidaemic donor by ultracentnfugation." To prevent modification of LDL during isolation, 1·0g/L EDT A, 2 mrnol/L Pefablock (Roche Molecular Biochemicals, Lewes, UK) and 0·5 giL sodium azide were added to the plasma sample. Protein concentrations were determined using the bicinchoninic acid assay (Pierce, Rockford IL, USA) with bovine serum albumin (BSA) as a standard." Purity of the LDL preparation was confirmed by discontinuous sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SOS-PAGE) on 3-15% linear gradient gels,22 and by electrophoresis on 1% agarose gels. 23 Desialylated LOL was prepared by incubation with agarose-immobilized neuraminidase from Clostridium perfringens (type VI-A; Sigma-Aldrich, Poole, UK) following the method of Camejo et al," Briefly, LOL was treated with neuraminidase (0,5 U enzyme 24 The reaction was carried out in 20 mmol/L sodium phosphate, pH 7'5, containing 50mmoi/L EOTA and 5g/L I-O-n-octyl-!1-D-glucopyranoside (SigmaAldrich) at a ratio of 0·048 U enzyme/ug IgG. Deglycosylation of the antibody was assessed by lectin blotting with biotinylated RCA I 20, as previously described by Lundy and Wisdom.j" The deglycosylated antibody was stored at 4°C in the presence of I giL sodium azide. . Plates were washed as described previously and 100JlL each of desialylated LOL standard or serum sample, diluted in TBST containing 30 giL BSA added (two replicates) before incubation for 3 h at 37°C. Subsequent incubation steps were performed in this buffer unless stated otherwise. Serum samples were diluted (either 1:1000 or 1:2000) so their concentration of apo B-100 fell within the linear portion of the calibration curve. Plates were washed as before and 100ilL of a 1:500 dilution of biotinylated RCA 120 (i.e. 4 mg/L) added before an overnight incubation at 4°C. Unbound lectin was removed by washing and 100ilL of a I: 1000 dilution of streptavidlnalkaline phosphatase conjugate (Vector Laboratories, Peterborough, UK) added before incubation for 3 h at 37°C. A final washing step was carried out and 100ilL of a I g/L solution of p-nitrophenyl phosphate in 10mmol/L diethanolamine buffer, pH 9,5, containing 0·5 mmol/L magnesium chloride and 0·2 giL sodium azide were added. After a 10min incubation at room temperature, the reactions were stopped with 50 ilL of 2 mol/L sodium hydroxide and the absorbance of each well determined at 405 nm in a microtitre plate reader (Multiscan MS; Labsystems, Helsinki, Finland).
Units of measurement
Results were expressed as total serum concentrations of asialo-LDL and, to standardize the data for LOL concentrations, as a percentage of the total concentration of apo B-100 within each sample. These percentage values were described as an LDL 'asialylation index'.
Statistical analysis Data were analysed for a normal distribution using the One-Sample Kolmogorov-Smirnov test. Gender distribution between the control and CAD groups was compared using the Chisquare test. The age of the control and atherosclerotic populations was compared using the Welch unpaired two-tailed r-test, due to unequal variance of the data. Total cholesterol, LDL and HDL cholesterol and apo B-IOO concentrations were compared using the Student's unpaired two-tailed r-test, due to equal variance of the data. Triglyceride and asialo-LDL values were analysed using the MannWhitney non-parametric test of significance, with the data expressed as the median and interquartile range OQR). For asialo-LDL values, 95% confidence intervals (95% CI) at the median value were also calculated. Correlations were analysed by calculation of Spearman's rank order coefficients. Probability values (P)<0·05 were considered statisticaIly significant.
RESULTS
Desialylation of LDL LDL was desialylated with neuraminidase for 24 h and used as a standard to calibrate the antibody-lectin assay. Loss of sialic acid was confirmed by electrophoresis on 1% agarose gels. The neuraminidase-treated LDL standard had a relative mobility of 0·75 compared to native LDL. Incubation with neuraminidase for an additional 24 h did not produce any further change in mobility. The observed decrease in electrophoretic mobility of the modified lipoprotein towards the anode demonstrated a reduction in the overaIl negative charge on the LDL particle due to the removal of terminal sialic acid residues. These results are similar to those reported by Myara et al. 26 SDS-PAGE of the neuraminidase-treated LDL preparation revealed no fragmentation of apo B-lOO, thereby demonstrating negligible degradation of the protein during desialylation.
Deglycosylation of anti-human apo B IgG
Preliminary studies demonstrated reaction between RCA 120 Fig. I ). The problem was overcome by deglycosylation of the antibody with peptide-N-glycosidase F prior to coating of the microtitre plate weIls. Deglycosylation reduced the reactivity between the antihuman apo B IgG molecules and RCA m by approximately 98%. Lectin blotting of the deglycosylated IgG sample further confirmed abolition of the reaction between RCA I20 and the y chain of the antibody (see Fig. I ).
Optimization of the antibody-lectin sandwich assay Components of the antibody lectin assay were investigated for optimal concentrations. Initial experiments revealed low background absorbance when weIls were blocked with BSA and incubations were performed in a TBST buffer containing BSA. Three different coating concentrations of deglycosylated anti-human apo B IgG (2,0, 1'0 and 0·5 jlgjweIl) were examined for their ability to capture different quantities of neuraminidase-treated LDL. For these experiments, the biotinylated RCA 120 and streptavidin-alkaline phosphatase conjugate were both used at a dilution of I: 1000. With the same concentration of neuraminidase-treated LDL, increases in
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Performance of the antibody-lectin sandwich assay Figure 4 shows the calibration curves obtained for the assay using native and neuraminidasetreated LDL. The assay could accurately differentiate between native and desialylated forms of LDL within the concentration range 0·05-3·0mg/L. The lower detection limit of the assay for neuraminidase-treated LDL was calculated as signal were observed for all increases in antibody coating concentrations (see Fig. 2 ). Similarly, with the same amount of immobilized antibody, the signal increased within the assay range in proportion to the increase in concentration of desialylated LDL. On the basis of these results, an antibody coating concentration of I Jlg per well was selected for all future assays. This was a compromise between maximum capture of LDL and economical use of the deglycosylated antibody. Three dilutions of biotinylated RCA 120 (I :500, I: 1000 and I:2000) were examined for the measurement of neuraminidase-treated LDL. For these studies, streptavidin-alkaline phosphatase was again used at a dilution of I: 1000. The I:500 dilution (i.e. 4 mg/L) of biotinylated RCA I20 gave the best sensitivity and signal-tonoise ratio and was therefore selected for all further experiments (see Fig. 3 ).
The concentration of streptavidin-alkaline phosphatase was not examined any further since a I: 1000 dilution of the conjugate produced a satisfactory signal with a I:500 dilution of the lectin and did not give rise to any non-specific interactions with other assay components. In these optimization experiments, the substrate was incubated for 15min before the addition of stop solution. However, for all subsequent experiments the substrate incubation time was 0·0 I mg/L, the concentration 2 standard deviation (SO) points above the background value of 12 wells containing all the assay components except analyte." The capacity of the assay to discriminate between native and desialylated forms of LOL demonstrated that sialic acid depletion did not significantly affect the ability of LOL to interact with the capture antibody.
To confirm the specificity of the assay, RCA I20 was treated with D-gal for 20 min at room temperature prior to its incubation with antibody-bound neuraminidase-treated LOL. The reactivity of RCA 120 was abolished, demonstrating specificity of the lectin for exposed D-gal residues on the lipoprotein (see Fig. 5 ). In addition, abolition of the assay signal in the absence of either the deglycosylated capture antibody, lectin or streptavidin-alkaline phosphatase conjugate further demonstrated that the signal did not originate from non-specific interactions between components (data not shown). Similar control experiments in which human serum replaced the neuraminidase-treated LDL standard produced the same results (data not shown).
Intra-and inter-assay precisions were determined with three different concentrations of neuraminidase-treated LOL, selected to cover the top. middle and bottom regions of the standard curve. Intra-assay SO was determined by measuring each sample 12 times (two replicates) during one run. Inter-assay SO was calculated by measuring each sample (two replicates) on six different days. The intra-assay coefficient of variation (CV) for 0·2, 0·8 and 3·0 mgjL concentrations of neuraminidase-treated LOL were 6'12, 4·20 and 2·41%, respectively, while the inter-assay CVs for these three concentrations were 7'65, 6·54 and 4,47%, respectively. Assay CVs based on the total precision SO ranged from 5·08% to 9·69%.
Recovery experiments were performed by analysing a serum sample containing 200 mgjL asialo-LOL before and after the addition of 100 and 500 mgjL of neuraminidase-treated LOL. The percentage recovery of analyte (± SO) was 93% (±4%) and 96% (±2%), respectively. The performance of the assay was further investigated by measuring asialo-LOL in serum and LOL fractions prepared from the same blood samples. A correlation coefficient of 0·88 (n=7, P<O·OI) demonstrated that levels of the modified lipoprotein could be accurately measured in serum without interference from other components.
Measurement of asialo-LDL in control and CAD subjects Concentrations of total asialo-LOL in the serum of control and atherosclerotic subjects were calculated from a standard curve constructed with neuraminidase-treated LOL. Asialo-LOL was detected in all the serum samples analysed. This was confirmed by lectin-blotting analysis with RCA I2o, which demonstrated asialo-apo B-100 in each sample (data not shown). Lectinblotting experiments also revealed that levels of asialo-apo (a) in the serum of our subjects were very low or negligible compared with levels of asialo-apo B-100 (data not shown). Figure 6 shows the total concentration of asialo-LDL measured for the individuals in both groups. Concentrations ranged from 115-998 mg/L for the control subjects and 144-990 mg/L for the CAD patients, with median concentrations of 240mg/L (lOR 180-3IOmg/L) and 220mg/L (lOR 186-390mg/L), respectively. The 95% CI for the control and CAD populations were 190-300mg/L and 195-360mg/L, respectively. Differences between the control and patient group for total concentrations of asialo-LDL were not statistically significant (P= 0,82) . Levels of total asialo-LDL were also expressed as a percentage of the total concentration of apo 8-100 in each sample, thus standardizing the data for LDL concentrations, which naturally vary between individuals. These percentage values were described as an 'asialylation index'. Figure 7 shows the results obtained for both populations. Asialylation index values ranged from 13 to 83% for the control subjects and from 12 to 53% for the CAD patients, with median values of 18% (lOR 16-23%) and 19% (lOR 15-29%), respectively. The 95% Cl for the control and CAD populations were 17-22% and 16-26%, respectively. No statistically significant difference was found between the two groups (P= 0,78). Only two subjects were found to have LDL with a marked level of sialic acid depletion. These were a 51-year-old female patient with an asialylation index of 53%, who had suffered a myocardial infarction, and a 34-year-old female control subject with an index value of 83%. The presence of sialic acid-poor LDL in the blood of certain healthy subjects has been observed before.S? All the other samples investigated had asialylation indexes that ranged from 12 to 40%.
Over the course of the study, levels of asialo-LDL were also examined in serum prepared from a small number of young (22-30 years), healthy volunteers (n = 10). The median asialylation index for this group was 19·5% (lOR 15'5-24°/0), with 95% CI of 14-25%. These results were not significantly different from either the control (P = 0,85) or CAD populations (P=0·84).
No correlations were observed between LDL asialylation index and age, total cholesterol, LDL and HDL cholesterol, triglycerides or apo 8-100 concentrations. Since asialo-LDL may have value as a riskfactor for CAD, the aim of our study was to develop an efficient assay that could measure this modified form of LDL in the serum of patients with angiographically-confirmed coronary artery stenosis and age-matched controls. The assay we developed combined a solid-phase anti-human apo 8 antibody to capture LDL from serum and the lectin RCA I20 to measure Dgal residues on the lipoprotein. This particular assay format was selected over the alternate lectin capture methodology, 16 since previous studies in our laboratory have found human serum to contain a large population of asialylated protein glycoforms that can compete for binding to RCA12o.25 In addition, investigations by Parkkinen" found that RCA I20 undergoes a reduction in binding affinity when immobilized to microtitre plate wells. The new assay proved to have good precision, could easily discriminate between both sialic acid-rich and -poor forms of LDL, and was relatively rapid and straightforward to use. In addition, good correlations were observed between asialo-LDL determinations in serum and LDL fractions prepared from the same blood, confirming the previous studies of
DISCUSSION

Tertov et al."
We applied our assay to serum samples taken from CAD patients living in Northern Ireland (a country with some of the highest levels of atherosclerosis in the world) as well as agematched control subjects. In addition, we also analysed a small population of young healthy volunteers. Asialo-LDL could be detected and measured in all the samples investigated, demonstrating that this modified form of LDL exists even in individuals with little or no atherosclerosis. The detection of sialic aciddepleted glycan chains on apo B-IOO from healthy subjects has been previously described by Taniguchi et al. 13 Their studies revealed that LDL contains a small proportion of monoasialylated biantennary chains that results in three to four exposed n-gal sugar residues per apo B-IOO polypeptide. The presence of these mono-asialylated oligosaccharides on apo B-IOO has been confirmed by Grewal et al. 29 and, more recently, Bartlett and Stanley. IS Indeed, the latter study revealed that all LDL particles in blood are partially asialylated and therefore capable of interaction with RCA 120'
When total concentrations of asialo-LDL in the CAD population were compared with those of control subjects, no statistically significant difference could be established, even after correction for concentrations of apo B-IOO. The absence of any difference between our two study populations contrasts with the previous reports of Orkehov et al. 3 .5. 9 and Tertov et al., 4 which clearly demonstrated the presence of significantly elevated concentrations of asialo-LDL in the blood of CAD patients, as measured by colorimetric assay of LDL sialic acid levels and RCA I 20 affinity chromatography. Also, similar studies by Ruelland et al. 6 found significant reductions (approximately 1'5-fold) in the sialic acid content of LDL in patients with CAD compared with control subjects, while Lindbohm et al.' reported a low sialic acid-to-apo B ratio in LDL from middle-aged women with CAD compared with healthy female controls. For many of these previous studies, significant differences between the patient and control groups were established using sample sizes no greater than those used in our own study.
Explanations for the differences between our results and those previously described are difficult to provide. However, it is interesting that a number of other groups have also been 30 could not demonstrate any significant decrease in the sialic acid content of LDL in 160 asymptomatic hypercholesterolaemic subjects with subclinical coronary and extracoronary atherosclerosis. Melajarvi et al." reported no significant difference in the sialic acid content of LDL prepared from type 2 diabetic and non-diabetic patients with and without advanced CAD. In fact, levels of sialic acid were found to be higher in the diabetic group compared with the non-diabetic controls, irrespective of the presence of CAD. This contrasts with the results of Sobenin et al. 8 Similar studies by Ruelland et al. 32 also found that type 2 diabetic patients with good glycaemic control as well as normal blood lipid concentrations had LDL sialic acid levels which were not significantly different from healthy, age-matched controls. More recent investigations by Chappey et al. 33 focused on the possibility that asialo-LDL levels are only elevated in the advanced stages of atherosclerosis. However, analysis of 100 patients with advanced coronary stenosis revealed no significant difference in LDL sialic acid content compared with LDL from healthy controls. Indeed, the sialic acid content of LDL was found to increase in patients with both coronary stenosis and peripheral arterial stenosis, compared with control subjects or patients with coronary or peripheral stenosis only. Furthermore, the sialic acid content of LDL prepared from 20 patients with acute myocardial infarction was significantly higher compared with the control population and angiographed CAD patients. These results therefore suggest that levels of asialo-LDL are reduced with the extension of atherosclerosis and its progression to acute complications. No correlations were established between asialylated LDL and age or blood lipoprotein profile. This is similar to the results reported here. Very recently, studies by Fujioka et al. 34 also revealed no difference in the structure of the oligosaccharides, or ratio of acidic sugar chains, in apo B-IOO from CAD patients compared with results for healthy individuals.
It is clear that the role asialo-LDL plays in atherosclerosis remains unresolved. It does not appear that the discord between results reflects regional or ethnic factors since the contradictory results of Ruelland et al. 6 and Chappey et al. 33 were both based on the study of CAD patients residing in France. In addition, Orkehov et al. 9 demonstrated that asialo-LDL isolated from subjects in Moscow and Houston had strictly similar properties. It could be suggested the differences between results may reflect variations in methodology. We measured asialo-LDL levels using a microtitre plate-based antibody-lectin sandwich assay that detected exposed o-gal sugars on the lipoprotein, while other groups have directly measured the sialic acid content of isolated LDL by colorimetric assay3-7.9.1O.14 or used lectin-affinity chromatography to separate sialic acid-rich and -poor forms of LDL. 4.9,1O.14 However, such an explanation appears very unlikely since studies in which elevated concentrations of asialo-LDL have been observed in CAD patients!" were based on colorimetric assay protocols identical to those used in investigations in which no increase in asialo-LDL levels was found. 30,31,33 In addition, the sialic acid content of LDL in the control groups used in these contradictory studies were often very similar, providing further evidence that differences were not due to variations in laboratory methods. One alternative possibility for the discordance in our results could be continued processing of the oligosaccharide chains on patients' LDL resulting in the loss of terminal D-gal sugars, in addition to sialic acid. Under such circumstances, reduced RCA I20 binding would occur and the degree of asialo-LOL would be underestimated. However, Tertov et al. 14 have shown that levels of D-gal in sialic acid-poor apo B-100 prepared from patients with CAD are not significantly different from levels in sialic acid-rich apo B-IOO from healthy subjects. Also. previous work has shown that sialic acid-poor LOL from CAD patients has a greatly increased capacity to interact with RCA I20 compared with LDL from healthy subjects, further demonstrating that terminal o-gal residues are not lost to any significant extent from the asialylated lipoprotein. 4.9,10.14 It is therefore very unlikely the absence of any significant difference in asialo-LOL levels between our CAO and control populations reflects the preferential loss of n-gal sugars on LOL from the atherosclerotic patients. One explanation that has been proposed for the observed increase in asialo-LOL during atherosclerosis, and based on experimental data, is that increased asialylation is an artefact produced by in vitro peroxidation reactions in isolated LOL. 33 As LOL from patients with CAD is more susceptible to oxidation than that from healthy individuals.Pr'" this may provide a plausible explanation. Further studies will be required to substantiate this possibility firmly. In addition, as recently suggested by Millar,37 many more general questions concerning the exact role sialic acid plays in lipoprotein function and clearance/uptake need to be addressed. With such knowledge, the importance of asialo-LDL in atherogenesis should become clearer.
To conclude, we have developed a convenient antibody-lectin assay for the analysis of asialo-LOL in purified LDL fractions and serum. This assay should prove useful in further studies of asialylated glycoforms of this lipoprotein.
